公开(公告)号：US20160207988A1

公开(公告)日：2016-07-21

申请号：US15024357

申请日：2014-09-23

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Yihong WAN

IPC: C07K16/18 ,  A61K45/06 ,  A61K38/18

CPC classification number: C07K16/18 ,  A61K38/1825 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/76

Abstract: The disclosure describes the use of anti-IGFBP1 antibodies to inhibit the bone loss-inducing properties of FGF21. This can be applied in the context of FGF21 treatment for obesity and/or diabetes, or in menopause-induced bone loss, such as osteoporosis.

Abstract translation: 本公开描述了使用抗IGFBP1抗体来抑制FGF21的骨损失诱导性质。 这可以用于FGF21治疗肥胖和/或糖尿病或更年期诱发的骨丢失如骨质疏松症的情况。

公开(公告)号：US20210095293A1

公开(公告)日：2021-04-01

申请号：US16098781

申请日：2017-05-05

Applicant: The Board of Regents of the University of Texas System

Inventor： Wing Yin CHENG ,  Yihong WAN ,  Peiwen CHEN

IPC: C12N15/113 ,  C12Q1/6886 ,  A61K31/4439 ,  G01N33/574

Abstract: The current disclosure describes therapeutic methods for treating cancer by inhibition of G protein-coupled receptor 132 (GPR132) in the tumor microenvironment. Aspects of the disclosure relate to a method for reducing and/or inhibiting cancer cell proliferation or tumor growth in a subject having cancerous cells or tumor growth, the method comprising administering an effective amount of an agent that inhibits GPR132 to the subject.

公开(公告)号：US20210371508A1

公开(公告)日：2021-12-02

申请号：US17332790

申请日：2021-05-27

Applicant: The Board of Regents of the University of Texas System

Inventor： Ningyan ZHANG ,  Zhiqiang AN ,  Zhiqiang KU ,  Yihong WAN ,  Jing KRZESZINSKI

IPC: C07K16/18 ,  A61K45/06 ,  G01N33/574 ,  A61K47/68

Abstract: Provided herein are methods for treating cancer, such as breast cancer, by administering an inhibitor of NMES1. Further provided herein are NMES1 monoclonal antibodies which may be used to detect or treat cancer.

公开(公告)号：US20160250224A1

公开(公告)日：2016-09-01

申请号：US15024354

申请日：2014-09-24

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Yihong WAN

IPC: A61K31/551 ,  A61K31/472 ,  A61K9/00 ,  A61K31/454

CPC classification number: A61K31/551 ,  A61K9/0019 ,  A61K31/454 ,  A61K31/47 ,  A61K31/472 ,  A61K38/177 ,  A61K38/22 ,  A61K45/06

Abstract: The use of orexin 1 receptor antagonists and/or orexin 2 receptor agonists thereof in the treatment of bone loss diseases is described. Such conditions include osteoporosis, rheumatoid arthritis and other bone wasting diseases.

Abstract translation: 描述了食欲肽1受体拮抗剂和/或食欲肽2受体激动剂在治疗骨丢失疾病中的用途。 这些病症包括骨质疏松症，类风湿关节炎和其他骨消耗疾病。

公开(公告)号：US20160201056A1

公开(公告)日：2016-07-14

申请号：US14913005

申请日：2014-08-14

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Yihong WAN

IPC: C12N15/113 ,  A61K31/7088 ,  A61K45/06

CPC classification number: C12N15/113 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/713 ,  A61K45/06 ,  C12N2310/141 ,  C12N2320/30 ,  C12N2320/31

Abstract: The use of miR-34a and agonists thereof in the treatment of bone loss diseases is described. Such conditions include osteoporosis, rheumatoid arthritis and other bone wasting diseases.

Abstract translation: 描述了miR-34a及其激动剂在治疗骨丢失疾病中的用途。 这些病症包括骨质疏松症，类风湿关节炎和其他骨消耗疾病。